Effects of verteporfin therapy on contrast sensitivity: Results from the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation - TAP Report No. 4

Gary S. Rubin, Neil M. Bressler, Jennifer Arnold, Dara Kilmartin, John Olson, Sean Neville, Karon Robinson, Allison Laird, Claire Richmond, Alison Farrow, Sandra McKay, Rhona McKechnie, Gary Evans, Andrew P. Schachat, Neil M. Bressler, Susan B. Bressler, Pat Nesbitt, Tracey Porter, Patricia Hawse, Mike HartnettAnn Eager, Judy Belt, Dennis Cain, David Emmert, Terry George, Mark Herring, Jaquelyn McDonald, Jordi Monés, Borja Corcóstegui, Montse Gilbert, Nuria Duran, Maite Sisquella, Ana Nolla, Alfons Margalef, Joan W. Miller, Evangelos S. Gragoudas, Anne Marie Lane, Nicholas Emmanuel, Amy Holbrook, Claudia Evans, Ursula Szajta Lord, Davis K. Walsh, Charlene D. Callahan, Jennifer L. DuBois, Jennifer Moy, Alice George Kenney, Inge Milde, Eric S. Platz, Hilel Lewis, Peter K. Kaiser, Laura J. Holody, Erica Lesak, Susan Lichterman, Helene Siegel, Anthony Fattori, Ginny Ambrose, Tami Fecko, Deborah Ross, Stephanie Burke, Joyce Conway, Lawrence Singerman, Hernando Zegarra, Michael Novak, Michelle Bartel, Kimberly Tilocco-DuBois, Mary Ilc, Stephanie Schura, Sheri Joyce, Vivian Tanner, Pam Rowe, Sheila Smith-Brewer, Donna Kukula, Greg Greanoff, Geraldine Daley, John DuBois, David Lehnhardt, Gary Edd Fish, Bradley F. Jost, Rajiv Anand, David Callanan, Sally Arceneaux, Jean Arnwine, Penny Ellenich, John King, Hank Aguado, Rubye Collins, Teresa Anderson, Cynthia Nork, Karen Duignan, Bob Boleman, Constantin J. Poumaras, Guy Donati, Anastasios D. Kapetanios, Katty Cavalière, S. Guney-Wagner, N. Gerber, Michel Sickenberg, Valérie Sickenberg, Alice Gans

Research output: Contribution to journalArticlepeer-review

Abstract

Background: In the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation, verteporfin therapy reduced the risk of at least moderate vision loss (defined as a loss of at least 15 letters of visual acuity) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). This report presents detailed analyses of 24-month contrast sensitivity outcomes in these patients. Methods: The patients included in the TAP investigation had subfoveal CNV secondary to ARMD and received verteporfin therapy (n = 402) or placebo (n = 207) at the first visit, with retreatment at each 3-month follow-up visit if angiography revealed fluorescein leakage from CNV. Contrast sensitivity was determined at each visit using a Pelli-Robson chart. Results: At the month 24 examination, verteporfin-treated patients were less likely to lose at least 6 or 15 letters of contrast sensitivity than placebo-treated patients (86 [21%] versus 94 [45%], and 27 [7%] versus 24 [12%], respectively; P < 0.05 for both comparisons). The superiority of verteporfin therapy over placebo was greater in patients with predominantly classic CNV at baseline, although verteporfin-treated patients with minimally classic CNV also had better contrast sensitivity outcomes. Conclusions: Consistent with visual acuity outcomes, verteporfin therapy reduced the risk of a clinically relevant loss of contrast sensitivity in the total study population, with the greatest effect in patients with predominantly classic subfoveal CNV secondary to ARMD. Verteporfin-treated patients with minimally classic CNV also had better contrast sensitivity outcomes than patients who received placebo. Given the association between contrast sensitivity and visual disability, the beneficial effects of verteporfin therapy on contrast sensitivity outcomes are expected to have a favorable impact on patients' daily activities.

Original languageEnglish (US)
Pages (from-to)536-544
Number of pages9
JournalRetina
Volume22
Issue number5
DOIs
StatePublished - Oct 2002
Externally publishedYes

Keywords

  • Age-related macular degeneration
  • Choroidal neovascularization
  • Contrast sensitivity
  • Verteporfin
  • Visual function

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Effects of verteporfin therapy on contrast sensitivity: Results from the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation - TAP Report No. 4'. Together they form a unique fingerprint.

Cite this